When the P-value falls within the range of 0.017 and 0.05, it is categorized as nominally significant
GLP1 receptor agonists such as liraglutide, semaglutide, and dulaglutide are widely used in the management of type 2 diabetes and increasingly for weight management in people with and without diabetes
Once it receives FDA approval, it will likely be prescribed as a once-weekly injection, much like other medications in the GLP-1 agonist class
What matters most is: The receptor pathways activated (single, dual, or triple agonism) The degree of weight loss achieved at clinical endpoints The tolerability profile at each dose escalation By these measures, Retatrutides dosing strategy has set a new benchmark for weight-loss drugs currently under development
4.4.1 Clinical evidence and limitations An open-label RCT compared 12 weeks of MET versus MET + low-dose liraglutide (1.2 mg/d) as pretreatment before IVF in obese infertile women (with a 4-weeks washout)
Since retatrutide activates GIP receptors that enhance insulin sensitivity, some researchers theorize that morning injection could synergize with the natural morning insulin sensitivity peak to produce slightly better metabolic outcomes
